IRIS
TINARI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.080
EU - Europa 5.798
AS - Asia 5.402
SA - Sud America 828
Continente sconosciuto - Info sul continente non disponibili 716
AF - Africa 97
OC - Oceania 9
AN - Antartide 1
Totale 21.931
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.870
SG - Singapore 2.362
CN - Cina 1.390
IT - Italia 1.165
IE - Irlanda 800
BR - Brasile 652
UA - Ucraina 629
RU - Federazione Russa 607
SE - Svezia 564
VN - Vietnam 562
GB - Regno Unito 496
DE - Germania 465
FR - Francia 459
TR - Turchia 391
IN - India 223
FI - Finlandia 206
HK - Hong Kong 104
CA - Canada 99
BD - Bangladesh 92
NL - Olanda 69
BE - Belgio 63
PL - Polonia 62
MX - Messico 60
AR - Argentina 56
AT - Austria 54
JP - Giappone 53
IQ - Iraq 44
CZ - Repubblica Ceca 41
ZA - Sudafrica 35
ES - Italia 34
CO - Colombia 26
EC - Ecuador 22
LT - Lituania 21
PK - Pakistan 19
ID - Indonesia 18
EG - Egitto 17
JM - Giamaica 17
UZ - Uzbekistan 17
VE - Venezuela 16
CL - Cile 15
KR - Corea 14
PE - Perù 12
SA - Arabia Saudita 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
PY - Paraguay 11
MA - Marocco 10
MY - Malesia 10
AU - Australia 9
EU - Europa 9
GR - Grecia 9
KE - Kenya 9
PT - Portogallo 9
IL - Israele 8
IR - Iran 8
PH - Filippine 8
RO - Romania 8
TN - Tunisia 8
CH - Svizzera 7
JO - Giordania 7
NP - Nepal 7
AL - Albania 6
BG - Bulgaria 5
BO - Bolivia 5
CR - Costa Rica 5
DZ - Algeria 5
GT - Guatemala 5
KZ - Kazakistan 5
LB - Libano 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
AZ - Azerbaigian 4
HN - Honduras 4
OM - Oman 4
BY - Bielorussia 3
ET - Etiopia 3
GE - Georgia 3
MT - Malta 3
NI - Nicaragua 3
SN - Senegal 3
BA - Bosnia-Erzegovina 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
KW - Kuwait 2
LU - Lussemburgo 2
MD - Moldavia 2
PS - Palestinian Territory 2
SV - El Salvador 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BS - Bahamas 1
BW - Botswana 1
CI - Costa d'Avorio 1
CM - Camerun 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
Totale 21.206
Salva come PNG Salva come JPEG
Città #
Singapore 1.793
San Jose 1.048
Chandler 959
Dublin 785
Jacksonville 740
Ashburn 593
Dallas 426
Beijing 372
Council Bluffs 335
Princeton 319
Southend 294
Los Angeles 244
Nanjing 220
Izmir 212
Santa Clara 211
The Dalles 194
Munich 188
Pescara 181
Ann Arbor 178
New York 166
Ho Chi Minh City 161
Chieti 159
Wilmington 146
Dearborn 134
Hanoi 126
Altamura 121
Boardman 119
Cambridge 111
Tongling 91
Buffalo 90
Hong Kong 89
Moscow 74
Nanchang 71
São Paulo 71
Helsinki 67
Brussels 59
Woodbridge 58
Redondo Beach 54
Orem 52
Dong Ket 50
Rome 49
Tokyo 46
Vienna 44
Phoenix 42
Chicago 40
Montreal 40
Warsaw 39
Atlanta 38
Brooklyn 38
Milan 38
Amsterdam 37
Nuremberg 37
Columbus 36
Denver 36
Houston 36
Shenyang 34
Hebei 33
Brno 32
Ancona 31
London 31
Da Nang 30
Frankfurt am Main 30
Norwalk 30
Boston 29
Kunming 29
Tianjin 28
Chennai 27
St Louis 27
Jiaxing 26
Turku 26
Hefei 25
Johannesburg 25
Falls Church 24
San Francisco 24
Washington 24
Seattle 23
Stockholm 23
Changsha 21
Haiphong 21
Ascoli Piceno 19
Mexico City 19
Toronto 19
Baghdad 18
Hangzhou 18
Manchester 18
Poplar 18
Rio de Janeiro 18
Montesilvano 17
Hyderabad 15
Shanghai 15
Belo Horizonte 14
Düsseldorf 14
Kingston 14
Lappeenranta 14
Mumbai 14
Seoul 14
Tashkent 14
Campinas 13
Grevenbroich 13
Kraków 13
Totale 12.941
Salva come PNG Salva come JPEG
Nome #
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 361
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 282
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 212
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer 207
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 198
CD19.CAR-T cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy 189
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 189
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 188
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 184
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 179
Allergooncology: an expanding research area 176
CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy 174
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 172
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 170
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 169
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 164
ERBB3 BINDING ANTIBODY 163
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 161
Exosomes as pleiotropic players in pancreatic cancer 161
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 160
Prognostic relevance of LGALS3BP in human colorectal carcinoma 160
Occupational allergy: is there a role for nanoparticles? 159
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 158
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 158
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 157
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 156
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 156
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 154
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 153
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 150
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 150
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 149
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 149
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 148
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 148
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 147
New Targets for Therapy in Pancreatic Cancer 146
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 145
Multi-omics staging of locally advanced rectal cancer predicts treatment response: a pilot study 144
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 143
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 142
Novel inhibitors of pvhl-elongin c binding 139
A perspective analysis: microRNAs, glucose metabolism, and drug resistance in colon cancer stem cells 139
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 139
An FPSE-HPLC-PDA method for the determination of anticancer drugs in human whole blood, plasma, and urine 138
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 137
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 136
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 136
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 136
Flow Cytometry Detection of Anthracycline-Treated Breast Cancer Cells: An Optimized Protocol 135
Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion 135
A Stochastic Model for the HIV/AIDS Dynamic Evolution 134
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 134
Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer 133
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 132
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 132
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 132
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 131
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 130
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 130
A Flow cytometric study of early gastric cancer 129
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 128
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 128
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 128
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 128
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 127
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 127
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 126
The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody 125
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 125
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 124
Principali effetti collaterali delle terapie mediche 124
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 124
DNA ploidy and S-phase fraction in pulmonary carcinoids. 123
Tumor-derived microvesicles: The metastasomes. 123
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 123
Prognostic value of 90K protein in HIV infection 122
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 122
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 121
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 121
3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability 120
Prognostic value of a novel circulating serum 90K antigen in breast cancer 120
Role of 90K protein in asthma and TH2-type cytokine expression. 120
Unknown primary tumors 120
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 120
Drug repurposing, an attractive strategy in pancreatic cancer treatment: Preclinical and clinical updates 119
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 118
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 118
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 117
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 116
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 116
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 115
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 115
Prognostic value of gender and primary tumor location in metastatic colon cancer 115
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 114
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 113
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 113
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 113
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 112
Combinations of biological response modifiers: rationale and clinical responses. 112
Totale 14.413
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.699
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.699
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022834 0 0 15 174 78 37 35 69 59 22 94 251
2022/20232.683 216 341 202 307 267 483 147 236 300 22 103 59
2023/20241.415 121 46 79 63 85 457 236 54 41 40 15 178
2024/20253.722 178 606 501 105 87 184 344 237 357 216 392 515
2025/20267.366 599 320 802 846 702 464 1.202 420 747 667 404 193
2026/2027834 196 519 119 0 0 0 0 0 0 0 0 0
Totale 21.931